Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBridgewater Associates, LP
ManagerRay Dalio, Bob Prince
Latest Disclosed Ownership13,357 shares
Latest Disclosed Value $ 5,964,435
Bridgewater Associates, LP reports 51.41% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Bridgewater Associates, LP filed a 13F-HR form disclosing ownership of 13,357 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $5,964,435 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 27,488 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -51.41% during the quarter. The current value of the position is $5,968,308 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,357 -14,131 -51.41 5,964 -52.14 0.0266
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 27,488 -10,836 -28.27 12,462 -16.98 0.0454
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 38,324 3,934 11.44 15,009 -1.97 0.0588
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,390 34,390 15,310 0.0618
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -710 -100.00 0 -100.00
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 710 -2,742 -79.43 286 -82.24 0.0013
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,452 -29,777 -89.61 1,605 -89.70 0.0091
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 33,229 -101,466 -75.33 15,575 -72.34 0.0813
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 134,695 2,341 1.77 56,304 4.55 0.2847
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 132,354 -25,995 -16.42 53,854 -2.20 0.3015
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 158,349 -17,964 -10.19 55,064 -11.25 0.3328
2023-08-11 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 176,313 -27,963 -13.69 62,046 -3.60 0.3832
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 204,276 103,457 102.62 64,361 121.07 0.3927
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 100,819 -63,172 -38.52 29,115 -38.68 0.1589
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 163,991 -53,161 -24.48 47,482 -22.40 0.2404
2022-08-11 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 217,152 187,000 620.19 61,191 677.62 0.2593
2022-05-13 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,152 17,735 142.83 7,869 188.56 0.0317
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,417 -2,700 -17.86 2,727 -0.55 0.0159
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,117 -8,139 -35.00 2,742 -41.52 0.0150
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,256 1,567 7.22 4,689 0.60 0.0301
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,689 18,059 497.49 4,661 443.24 0.0411
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,630 3,630 858 0.0074
2020-02-13 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -32,260 -100.00 0 -100.00
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,260 32,260 5,465 0.0480
2019-08-13 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -21,889 -100.00 0 -100.00
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 21,889 21,889 4,026 0.0247
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -15,509 -100.00 0 -100.00
2018-08-13 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,509 15,509 2,636 0.0263
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -18,673 -100.00 0 -100.00
2017-08-10 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,673 18,673 2,406 0.0220
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.